Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Standard
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. / Iwanski, Gabriela B; Lee, Dhong H; En-Gal, Shlomit; Doan, Ngan B; Castor, Brandon; Vogt, Marco; Toh, Melvin; Bokemeyer, Carsten; Said, Jonathan W; Thoennissen, Nils H; Koeffler, H Phillip.
in: BRIT J PHARMACOL, Jahrgang 160, Nr. 4, 4, 2010, S. 998-1007.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
AU - Iwanski, Gabriela B
AU - Lee, Dhong H
AU - En-Gal, Shlomit
AU - Doan, Ngan B
AU - Castor, Brandon
AU - Vogt, Marco
AU - Toh, Melvin
AU - Bokemeyer, Carsten
AU - Said, Jonathan W
AU - Thoennissen, Nils H
AU - Koeffler, H Phillip
PY - 2010
Y1 - 2010
N2 - Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.
AB - Pancreatic cancer is a highly aggressive malignancy, and improvement in systemic therapy is necessary to treat this frequently encountered metastatic disease. The current targeted agents used in combination with gemcitabine improved objective response rates, but with little or no improvements in survival and also increased toxicities in pancreatic cancer patients. Recently, we showed that the triterpenoid cucurbitacin B inhibited tumour growth in pancreatic cancer cells by inhibition of the JAK/STAT pathway, and synergistically increased antiproliferative effects of gemcitabine in vitro.
M3 - SCORING: Zeitschriftenaufsatz
VL - 160
SP - 998
EP - 1007
JO - BRIT J PHARMACOL
JF - BRIT J PHARMACOL
SN - 0007-1188
IS - 4
M1 - 4
ER -